Clinical Trial

Effect of Graded Motor Imagery in Impingement

Study acronym: Impingement
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Purpose: This randomized controlled trial aims to investigate the effects of Graded Motor Imagery (GMI) added to conventional physiotherapy in patients with Grade-2 shoulder impingement syndrome. The primary objectives are to evaluate the impact of GMI on pain intensity, range of motion, kinesiophobia, joint position sense, and quality of life. The hypotheses tested are: H0: GMI combined with conventional therapy has no effect on the aforementioned outcomes. H1: GMI combined with conventional therapy significantly improves these outcomes. Methodology: The study will include 30 participants (15 control, 15 intervention) diagnosed with Grade-2 shoulder impingement, recruited from a tertiary hospital. Participants will be randomly allocated into two groups: Control Group: Receives 15 sessions of conventional physiotherapy (ultrasound, TENS, hotpack, and therapeutic exercises). Intervention Group: Receives conventional therapy plus GMI, which includes three phases: (1) lateralization training (identifying left/right limb images), (2) motor imagery (mental rehearsal of functional movements), and (3) mirror therapy (visual feedback via mirror). Outcome measures include pain (Visual Analog Scale), range of motion (digital goniometer), joint position sense (mobile app-based assessment), kinesiophobia (Tampa Scale), upper extremity function (DASH questionnaire), and quality of life (SF-36). Pre- and post-intervention evaluations will be conducted.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-04.
Trial Details
NCT Number NCT06865001
Lead Sponsor Bandırma Onyedi Eylül University
Conditions Shoulder, Impingement Syndrome, Pain
Enrollment 30 participants
Start Date 2024-01-12
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-12